San Francisco, 10 May 2024: The Report STD Diagnostics Market Size, Share & Trends Analysis Report By Product (Instruments and Services, Consumables), By Application (HIV Testing, HSV Testing, Chlamydia Testing), By Technology, By Location Of Testing, By Region, And Segment Forecasts, 2024 - 2030

The global STD diagnostics market size is expected to reach USD 16.36 billion by 2030, expanding at a CAGR of 7.18% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing disease burden of Sexually Transmitted Disease (STD) and efforts by government & non-profit organizations to increase awareness and encourage regular screenings among the younger population are the key factors augmenting the market growth. According to WHO data, around 374 million new cases of syphilis, gonorrhea, chlamydia, and trichomoniasis are recorded every year globally.

Development and commercialization of advanced products, such as next-generation HIV testing kits and multiplex PCR products, enable physicians to timely diagnose & distinguish a range of STIs and provide appropriate treatment. Seegene, Inc., a South Korea-based diagnostic company, provides a wide portfolio of Allplex, Anyplex, and Seeplex products that detect various causative agents. For instance, Allplex STI/BV Panel Assay can distinguish 28 causative agents in a single test. In April 2022, Seegene, Inc. announced the development of Allplex HPV HR Detection.

Allplex HPV HR Detection is the world’s first commercialized ‘3 Ct’ PCR assay. Seegene is focusing to apply this technology to its entire product chain, including STI, Urinary Tract Infection (UTI), and Respiratory Virus (RV) assays. This strategic technological advancement is expected to provide an additional advantage to the company that can help increase its share in the Sexually Transmitted Disease (STD) diagnostics industry.

The HIV National Strategic Plan is a roadmap for eliminating the human immunodeficiency virus pandemic in the U.S. by 2030. The HIV Plan, which will run from 2021 to 2030, is the country's third five-year national HIV plan in a row, with a 10-year goal of halving new human immunodeficiency virus infections by 90% by 2030. Furthermore, the Viral Hepatitis National Strategic Plan focuses on hepatitis B and C, which are sexually transmitted. In January 2021, the US Department of Health and Human Services (HHS) released a nationwide strategy to address the preventable, substantial public health threats posed by viral hepatitis in the United States. The government's beneficial actions create a favorable atmosphere for the expansion of the STD diagnostics industry.

Companies are engaging in strategic initiatives that aid in the development of new products, and regulatory approvals as well as enhance their STD diagnostics product portfolio. For instance, in August 2020, DiaSorin, Inc. received 510 (k) approval from U.S. FDA for introducing LIAISON XL MUREX anti-HBe. It is used for the diagnosis of HBV infection. This immunoassay product works on the principle of chemiluminescence.

Request sample report of STD Diagnostics Market@ https://www.grandviewresearch.com/industry-analysis/diagnostic-testing-of-stds-market/request/rs1

The market for Sexually Transmitted Disease (STD) diagnostics is primarily influenced by advancements in diagnostic technology and increased government efforts to promote early detection and treatment. The growing burden of STDs serves as a key driver for the industry. Additionally, the growth can also be attributed to rapid technological advancements, and high R&D investments by key players to introduce novel & innovative products such as genetic biomarkers for antibiotic-resistant strains of bacteria, multiplex Point-of-Care (PoC), & self-testing products in the market.

STD Diagnostics Market Report Highlights

• In 2023, the consumables segment accounted for the largest market share and is anticipated to maintain its position over the forecast period owing to high testing rates for the diagnosis of STDs and the commercialization of several assays
• Based on technology, the molecular diagnostics segment is estimated to grow at the fastest CAGR during the forecast period owing to the increasing use of high-throughput PCR technology and the recommendation of NAAT tests for HIV testing. The development of multiplex PCR tests for the simultaneous detection of multiple pathogens is also expected to contribute to the STD diagnostics industry's growth
• Based on application, the HIV testing segment is expected to dominate the STD diagnostics industry in 2023, due to factors such as the high incidence rate of the disease, increasing product approvals for molecular tests, and favorable government initiatives
• Asia Pacific region is anticipated to experience the fastest growth over the forecast period due to an increase in testing rates for STDS, a rise in disposable income, and high disease prevalence of STD in developing countries

Technological advancements related to accuracy, portability, and cost-effectiveness are expected to drive the Sexually Transmitted Disease (STD) diagnostics market over the forecast period. Key players are expanding their test portfolios, by investing in R&D to develop diagnostic kits that can identify emerging diseases or by entering into agreements with other kit manufacturing companies. For instance, in June 2023, Linear Diagnostics, a UK-based company, a spinout from the University of Birmingham, secured funding to create a STI rapid test. The company received support from the National Institute for Health and Care Research (NIHR) in the UK. The funding aims to facilitate the development of a 20-minute test for diagnosing gonorrhoea and Chlamydia, addressing the need for faster and more accessible STI diagnostics.

In the ever-evolving landscape of STD diagnostics, key trends point towards integrating advanced technologies, contributing significantly to the industry's growth. The introduction of sophisticated tools, such as multiplex PCR products and next-generation HIV testing kits, stands out as a pivotal development. Companies such as Seegene, with products like Anyplex, Allplex, and Seeplex, have been crucial in expanding diagnostic capabilities. For instance, the Allplex STI/BV Panel Assay can distinguish among 28 different causative agents in a single test, showcasing the substantial progress made in diagnostic precision. This technological advancement not only broadens the spectrum of detectable sexually transmitted infections but also facilitates more accurate and targeted treatments.

STD Diagnostics Market Report Scope

Better reimbursement facilities overcome the high pricing issue to some extent in developed regions such as the U.S. and Europe. According to the World Health Organization (WHO), about 50% of healthcare financing in low-income countries comes from out-of-pocket payments, compared to ~14% in high-income countries and ~30% in middle-income countries. When payments from public health insurance, general government expenditure, and prepaid private insurance are combined, approximately 38% of healthcare financing in low-income countries is combined in funding pools, which allow the risks of healthcare costs to be shared across population groups, as compared to 80% in high-income countries and approximately 60% in middle-income countries.

List of Key Players in the STD Diagnostics Market

• BD
• F. Hoffmann-La Roche Ltd
• Hologic Inc.
• Abbott
• Cepheid (Danaher)
• Qiagen
• OraSure Technologies, Inc.
• Bio-Rad Laboratories, Inc.
• bioMérieux SA
• Thermo Fisher Scientific, Inc.
• Seegene Inc.
• DiaSorin S.p.A